Fostemsavir
- TRADE NAME: Rukobia (ViiV)
- INDICATIONS: HIV-1 infection
- SYNONYM: Fostemsavir tromethamine
- CLASS: Antiretroviral, Antiviral
- HALF-LIFE: 11 hours
FDA APPROVAL DATE: 07/02/2020
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Carbamazepine, CYP3A4 inducers, Enzalutamide, Mitotane, Phenytoin, Rifampin, St John's Wort
Insufficient human data to adequately assess a drug-associated risk of birth defects and miscarriage.
HIV-1–infected mothers are recommended not to breastfeed their infants.
Fostemsavir is a prodrug of temsavir.
Please login to see the rest of this drug profile
SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric